The stock of the week: “Castle Biosciences Inc”

The stock of the week: “Castle Biosciences Inc”

Castle Biosciences is our “stock of the week”. Castle Biosciences focuses on developing new tests for the diagnosis and prognosis of melanoma to improve decision making and patient care. Castle Biosciences announced today that TissueCypher Barrett’s Esophagus test results can significantly improve management decisions for patients that directly leads to improve health outcomes. This was very positive news for the company and shows how important the work on testing they are doing really is.

• Financial social media sentiment is “positive” in both absolute and relative terms – on its own and when compared to the sentiment of the sector and the sentiment of the stock index.

• Analysts' consensus rating is "buy" - out of the 7 bank analysts covering the company, all 7 recommend buying the stock. The upside potential of the stock price expected by the analysts on average over the next 6-12 months is currently 148.63% (reference close of business 24/10/2022).

• Attention buzz is currently “Average”.

Sources:

1. https://umushroom.com/en/equity/castle-biosci-rg

2. https://ir.castlebiosciences.com/news/news-details/2022/New-Data-Demonstrate-that-the-Utilization-of-TissueCypher-Barretts-Esophagus-Test-Results-Can-Significantly-Improve-the-Management-of-Low-Grade-Dysplasia-in-Patients-with-Barretts-Esophagus-over-the-Standard-of-Care-Alone/default.aspx